Study Details
A study of ASP3082 in adults with previously treated solid tumors
Clinicaltrials.gov ID
Astellas Study ID
3082-CL-0101
EudraCT ID
N/A
Condition
Advanced/Metastatic Cancer
Phase
Phase 1
Age
18 Years - N/A
Sex
Female & Male
Product
ASP3082
Type
Interventional
Trial Dates
Jun 2022 - Oct 2026
Masking
None (Open Label)
Enrollment number
356
A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study of ASP3082 in adults with previously treated solid tumors? Contact us by filling our your information to the right and we’ll respond to you.
Locations
NEXT Oncology
San Antonio, United States, 78229
Sarah Cannon Research Institute
Nashville, United States, 37203
Columbia University - Herbert Irving Comprehensive Cancer Center
New York, United States, 10032
Florida Cancer Specialists & Research Institute Sarasota
Sarasota, United States, 34232-6422
NEXT Oncology - Virginia Cancer Specialists
Fairfax, United States, 22031
Memorial Sloan Kettering Cancer Center
New York, United States, 10065
UCLA Santa Monica Hematology Oncology
Santa Monica, United States, 90404
University of Kansas Medical Center
Westwood, United States, 66205
Vanderbilt University Medical Center
Nashville, United States, 37232
Smilow Cancer Center at Yale New Haven Hospital
New Haven, United States, 06520-8028
Washington University School of Medicine
St. Louis, United States, 63110
Dana Farber Cancer Institute
Boston, United States, 02215
Cancer Institute Hospital of JFCR
Koto-ku, Japan
National Cancer Center Hospital
Chuo-ku, Japan
National Cancer Center Hospital East
Kashiwa, Japan